The role of nicotinic acetylcholine receptors in Alzheimer's disease

Salvatore Oddo, Frank M. LaFerla

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

The two hallmark lesions of Alzheimer's disease (AD) are extracellular amyloid plaques, mainly formed by a small peptide called amyloid-β (Aβ), and neurofibrillary tangles, which are intracellular inclusions formed by aggregates of hyperphosphorylated tau protein. One of the major neurochemical features of AD is the marked reduction of nicotinic acetylcholine receptors in disease-relevant brain regions such as the cerebral cortex and hippocampus. This loss is further compounded by the loss of cholinergic cells, which contributes to the cognitive dysfunction. This observation has had a major impact on therapeutic treatments, as efforts to restore cholinergic function such as the administration of acetylcholinesterase inhibitors have been, until recently, the major treatment options available for AD. Understanding the relationship of these hallmark lesions with the plethora of other changes that occur in the AD brain has proven to be a difficult challenge to resolve. The utilization of transgenic mouse models, that recapitulate one or more neuropathological and neurochemical features of the AD brain is providing some inroads, as they offer a means to gain mechanistic insights into the disease process in an in vivo setting. In this review, we consider the role of nicotinic acetylcholine receptors in transgenic models and in AD.

Original languageEnglish (US)
Pages (from-to)172-179
Number of pages8
JournalJournal of Physiology Paris
Volume99
Issue number2-3
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Nicotinic Receptors
Alzheimer Disease
Cholinergic Agents
tau Proteins
Neurofibrillary Tangles
Cholinesterase Inhibitors
Amyloid Plaques
Brain
Brain Diseases
Amyloid
Cerebral Cortex
Transgenic Mice
Hippocampus
Peptides

Keywords

  • Nicotine
  • Plaques
  • Tangles
  • Tau
  • Transgenic

ASJC Scopus subject areas

  • Neuroscience(all)
  • Physiology (medical)

Cite this

The role of nicotinic acetylcholine receptors in Alzheimer's disease. / Oddo, Salvatore; LaFerla, Frank M.

In: Journal of Physiology Paris, Vol. 99, No. 2-3, 03.2006, p. 172-179.

Research output: Contribution to journalArticle

@article{56c187974ffc48f7a11ad48ecf70e940,
title = "The role of nicotinic acetylcholine receptors in Alzheimer's disease",
abstract = "The two hallmark lesions of Alzheimer's disease (AD) are extracellular amyloid plaques, mainly formed by a small peptide called amyloid-β (Aβ), and neurofibrillary tangles, which are intracellular inclusions formed by aggregates of hyperphosphorylated tau protein. One of the major neurochemical features of AD is the marked reduction of nicotinic acetylcholine receptors in disease-relevant brain regions such as the cerebral cortex and hippocampus. This loss is further compounded by the loss of cholinergic cells, which contributes to the cognitive dysfunction. This observation has had a major impact on therapeutic treatments, as efforts to restore cholinergic function such as the administration of acetylcholinesterase inhibitors have been, until recently, the major treatment options available for AD. Understanding the relationship of these hallmark lesions with the plethora of other changes that occur in the AD brain has proven to be a difficult challenge to resolve. The utilization of transgenic mouse models, that recapitulate one or more neuropathological and neurochemical features of the AD brain is providing some inroads, as they offer a means to gain mechanistic insights into the disease process in an in vivo setting. In this review, we consider the role of nicotinic acetylcholine receptors in transgenic models and in AD.",
keywords = "Aβ, Nicotine, Plaques, Tangles, Tau, Transgenic",
author = "Salvatore Oddo and LaFerla, {Frank M.}",
year = "2006",
month = "3",
doi = "10.1016/j.jphysparis.2005.12.080",
language = "English (US)",
volume = "99",
pages = "172--179",
journal = "Journal de Physiologie",
issn = "0928-4257",
publisher = "Elsevier Masson SAS",
number = "2-3",

}

TY - JOUR

T1 - The role of nicotinic acetylcholine receptors in Alzheimer's disease

AU - Oddo, Salvatore

AU - LaFerla, Frank M.

PY - 2006/3

Y1 - 2006/3

N2 - The two hallmark lesions of Alzheimer's disease (AD) are extracellular amyloid plaques, mainly formed by a small peptide called amyloid-β (Aβ), and neurofibrillary tangles, which are intracellular inclusions formed by aggregates of hyperphosphorylated tau protein. One of the major neurochemical features of AD is the marked reduction of nicotinic acetylcholine receptors in disease-relevant brain regions such as the cerebral cortex and hippocampus. This loss is further compounded by the loss of cholinergic cells, which contributes to the cognitive dysfunction. This observation has had a major impact on therapeutic treatments, as efforts to restore cholinergic function such as the administration of acetylcholinesterase inhibitors have been, until recently, the major treatment options available for AD. Understanding the relationship of these hallmark lesions with the plethora of other changes that occur in the AD brain has proven to be a difficult challenge to resolve. The utilization of transgenic mouse models, that recapitulate one or more neuropathological and neurochemical features of the AD brain is providing some inroads, as they offer a means to gain mechanistic insights into the disease process in an in vivo setting. In this review, we consider the role of nicotinic acetylcholine receptors in transgenic models and in AD.

AB - The two hallmark lesions of Alzheimer's disease (AD) are extracellular amyloid plaques, mainly formed by a small peptide called amyloid-β (Aβ), and neurofibrillary tangles, which are intracellular inclusions formed by aggregates of hyperphosphorylated tau protein. One of the major neurochemical features of AD is the marked reduction of nicotinic acetylcholine receptors in disease-relevant brain regions such as the cerebral cortex and hippocampus. This loss is further compounded by the loss of cholinergic cells, which contributes to the cognitive dysfunction. This observation has had a major impact on therapeutic treatments, as efforts to restore cholinergic function such as the administration of acetylcholinesterase inhibitors have been, until recently, the major treatment options available for AD. Understanding the relationship of these hallmark lesions with the plethora of other changes that occur in the AD brain has proven to be a difficult challenge to resolve. The utilization of transgenic mouse models, that recapitulate one or more neuropathological and neurochemical features of the AD brain is providing some inroads, as they offer a means to gain mechanistic insights into the disease process in an in vivo setting. In this review, we consider the role of nicotinic acetylcholine receptors in transgenic models and in AD.

KW - Aβ

KW - Nicotine

KW - Plaques

KW - Tangles

KW - Tau

KW - Transgenic

UR - http://www.scopus.com/inward/record.url?scp=33645026907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645026907&partnerID=8YFLogxK

U2 - 10.1016/j.jphysparis.2005.12.080

DO - 10.1016/j.jphysparis.2005.12.080

M3 - Article

VL - 99

SP - 172

EP - 179

JO - Journal de Physiologie

JF - Journal de Physiologie

SN - 0928-4257

IS - 2-3

ER -